Categories: Health

AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th

PHOENIX and LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) — AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced that Wendy Blosser, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025.

DATE: September 18th
TIME: 2:30 pm EST
LINK: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5081546/accustem-sciences-inc-otcqb-acut
Available for 1×1 meetings: September 19-24

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

Ms. Blosser will be presenting on the exciting products in AccuStem’s portfolio and how they will address urgent unanswered clinical questions while returning significant value to investors.

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.  

Learn more about the event at www.virtualinvestorconferences.com.

About AccuStem

AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness”, we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.

For more information, please visit www.accustem.com.

About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access.  Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

CONTACTS:
AccuStem Sciences, Inc.
Jeff Fensterer
Chief Operations Officer
jeff@accustem.com

Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com

GlobeNews Wire

Recent Posts

AvironiX Unveils AviSpray-10c, a Backpack-Sized Agricultural Spraying Drone for India’s Precision Farming Sector

CHENNAI, India, Dec. 8, 2025 /PRNewswire/ -- AvironiX Drones, a Chennai-based deep-tech drone company focused on precision farming and defence technologies, today…

1 hour ago

Abstract and Open World Partner to Launch the First National-Scale Tokenization Engine for the World’s Most Valuable Real-World Assets

For the first time, the world's most strategic assets—AI supercomputing centers, strategic real estate and…

1 hour ago

Navitas, Cyient Semiconductors enter into a strategic partnership to accelerate GaN adoption in India’s AI, Mobility, Industrial, and Energy Markets

TORRANCE, Calif. and HYDERABAD, India, Dec. 8, 2025 /PRNewswire/ -- Navitas Semiconductor Corporation (Nasdaq: NVTS),…

1 hour ago

DXC Appoints Russell Jukes as Chief Digital Information Officer to Strengthen Unified Digital Strategy

ASHBURN, Va., Dec. 8, 2025 /PRNewswire/ -- DXC Technology (NYSE: DXC), a leading enterprise technology and…

1 hour ago

Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI

Latest release enables faster, more confident design decisions at scale with accelerated simulation, AI-powered, real-time…

1 hour ago

Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025

– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin…

1 hour ago